Crossmark

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib

Crossref DOI link: https://doi.org/10.1007/s00280-024-04698-w

Published Online: 2024-07-11

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Lishi

van der Noort, Vincent

Steeghs, Neeltje

Ruiter, Gerrina

Beijnen, Jos H.

Huitema, Alwin D. R.
License Information

Text and Data Mining valid from 2024-07-11

Version of Record valid from 2024-07-11
More Information

Article History

Received: 22 March 2024

Accepted: 5 July 2024

First Online: 11 July 2024

Declarations

:

: N.S. provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma, GlaxoSmithKline, Incyte, Luszana. N Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Lixte, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute.J.H.B. is a part-time employee and (indirect) shareholder of Modra Pharmaceuticals BV. He is (partly) patent holder of oral taxane formulations which are clinically developed by Modra Pharmaceuticals BV (a spin-off company of the Netherlands Cancer Institute), not related to this work.All other authors declared no conflicts of interest.

Document is current

Any future updates will be listed below